TG Therapeutics
TGTX
128 hedge funds and large institutions have $267M invested in TG Therapeutics in 2018 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 46 increasing their positions, 31 reducing their positions, and 26 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 31
5.4% more ownership
Funds ownership: 52.17% → 57.57% (+5.4%)
3% less funds holding
Funds holding: 132 → 128 (-4)
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
15% less call options, than puts
Call options by funds: $9.97M | Put options by funds: $11.8M
50% less capital invested
Capital invested by funds: $534M → $267M (-$267M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$44.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$22.3M |
| 3 |
Credit Agricole
Montrouge Cedex,
France
|
+$15M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.41M |
| 5 |
6CM
683 Capital Management
New York
|
+$5.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$9.65M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$8.57M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.1M |
| 4 |
CCI
Columbus Circle Investors
|
-$5.78M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$4.47M |
TGTX Hedge Fund Activity: Q3 2018 in Review
128 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2018, worth a combined $267M — down 50% from $534M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of TGTX and 22 opened new positions — a net loss of 4 holders — while 31 trimmed existing stakes and 46 added.
The largest buyer was RA Capital Management, adding an estimated $44.8M. The largest seller was Wells Fargo, cutting an estimated $9.65M.
- 128 institutional investors held TG Therapeutics (TGTX) as of Q3 2018, down from 132 in Q2 2018.
- Funds reported $267M of TG Therapeutics stock for Q3 2018, down 50% quarter-over-quarter.
- 22 funds opened new TG Therapeutics positions in Q3 2018 and 26 closed out, a net change of -4 holders.
- The largest TG Therapeutics buyer in Q3 2018 was RA Capital Management, an estimated $44.8M added.
- The largest TG Therapeutics seller in Q3 2018 was Wells Fargo, an estimated $9.65M sold.
Based on aggregated 13F filings for Q3 2018.